Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
US Army
AstraZeneca
Queensland Health
Accenture
Boehringer Ingelheim
UBS
Mallinckrodt
McKinsey

Generated: January 22, 2018

DrugPatentWatch Database Preview

BEPREVE Drug Profile

« Back to Dashboard

When do Bepreve patents expire, and when can generic versions of Bepreve launch?

Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in sixteen countries.

The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.
Summary for BEPREVE
International Patents:45
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 50
Clinical Trials: 5
Patent Applications: 15
Drug Prices:see details
DailyMed Link:BEPREVE at DailyMed
Drug patent expirations by year for BEPREVE
Pharmacology for BEPREVE

US Patents and Regulatory Information for BEPREVE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BEPREVE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 9/9/2013

Non-Orange Book US Patents for BEPREVE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,307,052 Acid-addition salts of optically active piperidine compound and process for producing the same ➤ Subscribe
7,282,589 Acid addition salt of optically active piperidine compound and process for preparing the same ➤ Subscribe
8,883,825 Aqueous liquid preparations and light-stabilized aqueous liquid preparations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for BEPREVE

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Johnson and Johnson
Healthtrust
AstraZeneca
US Army
UBS
Deloitte
Julphar
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot